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Abstract: Gabapentin enacarbil XR is a new extended-release formulation which attempts 
to overcome the reduced efficacy of shorter-acting gabapentin, with sustained delivery over 
a 24-hour period. It is a gabapentin prodrug which is efficiently and rapidly converted to 
gabapentin during active transport throughout the length of the intestine via high-capacity 
monocarboxylate type 1 nutrient transporters unlike its predecessor, which is absorbed via 
low-capacity transporters largely confined to the upper intestinal region. Its lack of saturable 
absorption allows for dose-proportional absorption and hence increased bioavailability. Several 
clinical trials addressing its efficacy in moderate to severe restless legs syndrome (RLS) dem-
onstrate improvements in the International RLS Rating Scale after a 2-week to 3-month period. 
Open-label studies of 52 weeks’ duration showed maintenance of symptom reduction with 
once-daily administration of the extended-release formulation. The most commonly reported 
treatment-emergent adverse effects were somnolence and dizziness. Although the incidence 
of emergent adverse effects is high, it is comparable with that of gabapentin. No studies thus 
far have documented augmentation as an issue, unlike that observed with most dopaminergic 
agents. In addition, both dopamine precursors and agonists have not been shown to increase 
slow wave sleep or improve overall sleep architecture consistently despite improvement in the 
periodic leg movement index, in contrast with gabapentin enacarbil. Presently, gabapentin 
enacarbil has not been approved by the Therapeutic Goods Administration or Medsafe for use 
in RLS. The cost of this medication may also be a potential barrier for many patients. Future 
comparative efficacy studies with gabapentin, first-line dopaminergic agents, rotigotine, being 
the other once daily RLS medication, and pregabalin, the structural analog of gabapentin, will 
be necessary.
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Introduction
Restless legs syndrome (RLS) affects 4%–14% of the adult population, depending on 
the rigorousness of the definition applied.1 It is twice as common in women, and has 
a prevalence of 2% in the pediatric population.2,3 RLS is a sensorimotor disorder, in 
which there is an irresistible urge to move the leg, although it can progress to involve 
other parts of the body, including the arms, trunk, and head.4 Often it is described as 
unpleasant, creeping, and crawling sensations or paraesthesias deep in the legs. These 
are particularly problematic during periods of rest, classically relieved by movement and 
worse in the evenings. The prior three features are also part of the essential diagnostic 
criteria of RLS alongside the urge to move the legs.5,6 Other non-essential but supportive 
features of RLS include a positive family history, response to dopaminergic agents, and 
periodic leg movements.6 Several aspects of a patient’s life can be influenced by RLS, 
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including difficulty with sleep initiation and maintenance, 
mood, cognitive function, and quality of life.7–9 While pri-
mary (idiopathic) RLS affects the majority of patients with 
this disorder, secondary RLS can also occur in patients with 
predisposing conditions, including iron deficiency, chronic 
renal failure, and pregnancy.10–12
A decision to treat RLS is based mostly on symptom 
  severity, frequency, and impact on quality of life.13 An esti-
mated 3% of patients with RLS are started on treatment at a gen-
eral practitioner’s office for moderate to severe   symptoms.14 
Sleep diaries and validated symptom rating scales can be 
utilized to assess the benefits of an intervention compared 
with baseline.15,16 Both non-pharmacologic and pharmaco-
logic treatment options are employed for the management 
of RLS. Although there is limited published evidence for the 
former, there are several non-pharmacological approaches 
that are utilized for milder RLS. These include partaking in 
mentally stimulating activities, improving sleep hygiene, 
lower body resistance training, aerobic exercise, weight loss, 
and pneumatic compression stockings.17–20 A reduction in 
alcohol, tobacco, and caffeine is also advised.21
With respect to vitamin and mineral supplementation, iron 
replacement to a goal ferritin of 50 µg/L for patients with iron 
deficiency (with or without anemia) and treatment of folate 
deficiency during pregnancy may help alleviate symptoms 
of RLS.15,22–24 Magnesium is currently being investigated as 
a potential treatment for RLS, with one small open-label 
study showing an improvement in symptoms and sleep effi-
ciency. However, a randomized controlled trial in pregnant 
patients with RLS did not demonstrate relief of symptoms 
with 360 mg of magnesium daily.25,26
The first-line pharmacotherapy for RLS is the dopamin-
ergic agents.  These include levodopa carbidopa or levodopa 
benserazide, which are dopamine precursors, as well as 
several dopamine agonists, such as pramipexole, ropinirole, 
and rotigotine. While dopamine agonists have a longer dura-
tion of action and an estimated 50% decrease in incidence 
of augmentation in comparison with dopamine precursors, 
one third of patients will continue to develop progressive 
worsening of symptoms on therapy.27,28 With augmentation, 
symptoms start to occur earlier in the day, become more severe 
in intensity and may affect other parts of the body, including 
the arms and trunk.29 The pathophysiology of augmentation 
remains unclear and treatment is challenging, being largely 
based on clinical consensus and expert opinion.29 Impulse 
control disorders, including gambling and compulsive shop-
ping, can also occur in up to 17% of patients, much like in 
Parkinson’s, which can result in serious social   consequences.30 
Rotigotine is a long-acting transdermal agent with good 
5-year efficacy and tolerability and may be particularly useful 
for patients with both daytime and night-time symptoms.31 
However, in a recent 5-year, open-label extension study, 
13% of patients developed clinically significant aug-
mentation and 58% developed mostly mild to moderate 
skin reactions at the application site.31 In addition, it is cur-
rently more expensive than other dopamine agonists.
Second-line agents include low potency opioids, ben-
zodiazepines, and gabapentin. With no controlled trials 
on opioids and limited randomized controlled trials on 
benzodiazepines, these agents presently remain off-label 
therapeutic options.32,33 Early morning sedation, tolerance, 
and dependence are potential challenges with these medica-
tions. Anticonvulsants like gabapentin are particularly useful 
for painful RLS.34 A double-blind, randomized, placebo-
controlled crossover study in 24 RLS subjects showed a 
significant reduction in RLS severity with gabapentin when 
dosed twice a day.34 In addition, small clinical trials have also 
demonstrated better RLS symptom relief with gabapentin 
than with levodopa in hemodialysis patients and compa-
rable improvements with ropinorole.35,36 The side effects are 
generally mild to moderate in nature, and include dizziness, 
somnolence, and peripheral edema. However, its efficacy is 
limited by its short half-life.34 Another anticonvulsant being 
investigated for RLS is pregabalin, a gabapentin analog 
which acts on the α2δ subunit of the voltage-dependent Ca2+ 
channel like gabapentin. There are currently two published, 
double-blind, randomized, controlled studies lasting 6–12 
weeks, showing a reduction in RLS symptoms over placebo, 
but future comparative efficacy and longer-term studies are 
necessary.37,38
In April 2011, the US Food and Drug Administration 
approved a new long-acting gabapentin (gabapentin enacarbil 
XR, HorizantTM) which attempts to overcome the reduced 
efficacy of shorter-acting gabapentin, with sustained delivery 
over a 24-hour period. Presently, medications listed for the 
management of RLS by the Therapeutic Goods Administra-
tion in Australia are pramipexole, ropinirole, and rotigotine. 
New Zealand’s Medsafe has approved pramipexole for RLS. 
This article reviews the current literature on the pharmacol-
ogy, pharmacokinetics, and clinical trials on gabapentin 
enacarbil and discusses its practical implications in the 
management of RLS.
Pharmacology and pharmacokinetics
Gamma-aminobutyric acid (GABA) is the principal inhibi-
tory neurotransmitter in the human central nervous system.39 
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Gabapentin is a GABA analog but is not believed to 
act on the same receptors. Instead, it acts on the α2δ 
subunit of the voltage-dependent Ca2+ channel.40 This 
interaction reduces calcium influx into the presynaptic 
nerve terminals and results in inhibition of excitatory 
neurotransmitter release.40 The drug is absorbed via low-
capacity transporters in the upper intestinal region. These 
transporters become saturated at the recommended doses, 
and increasing doses beyond the suggested dose range 
results in decreased bioavailability.41 A 600 mg dose had 
an average bioavailability of 50%, whereas daily 3600 mg 
doses resulted in a reduced bioavailability of 40%.42,43 
Wide variation in interpatient bioavailability may also be 
observed.43 Gabapentin has a half-life of 5–7 hours and is 
excreted by the kidney without appreciable metabolism.
Gabapentin enacarbil XR is a gabapentin prodrug which 
is efficiently and rapidly converted to gabapentin during 
active transport throughout the length of the intestine via 
high-capacity monocarboxylate type 1 nutrient transporters.44 
An open-label, single-center Phase I study of 14 healthy male 
volunteers demonstrated up to 85% recovery of a radioac-
tive dose in urine within 24 hours of 14C-labeled gabapentin 
enacarbil dosing.45 Levels of intact prodrug were low and 
transient.44 Unlike gabapentin, its lack of saturable absorp-
tion allows for dose-proportional absorption.46 In a study 
performed in healthy volunteers, extended-release gabap-
entin had a bioavailability of 83% and 72%, respectively, at 
doses of 350 mg and 2100 mg, whereas bioavailability was 
reduced at 65% and 27%, respectively, with doses of 200 mg 
and 1400 mg of gabapentin.46 Consuming the drug with 
meals, regardless of fat or caloric content, further increased 
its bioavailability in a small randomized, cross-over, open-
label study and several Phase I trials.46,47 In patients with 
renal impairment, dosage adjustment is necessary because 
its elimination is proportional to creatinine clearance.48 No 
dose adjustments were needed when coadministered with 
either 500 mg naproxen twice daily or 400 mg cimetidine 
four times a day.49 Like gabapentin enacarbil, naproxen 
is also a substrate for the high-capacity monocarboxylate 
type 1 nutrient transporter in the intestine and cimetidine is 
a substrate for the organic cation transporter in the kidney, 
by which elimination of extended-release gabapentin occurs. 
Hence no clinically relevant pharmacokinetic interactions 
are expected between gabapentin enacarbil and other 
substrates of these transporters.49 Overall, the improved 
pharmacokinetics of this extended-release formulation 
compared with gabapentin thus allows for its once-daily 
administration.
Clinical trials
Efficacy
There are currently seven published clinical trials which 
address the efficacy of gabapentin enacarbil. The study 
characteristics, primary endpoints, and results of these trials 
are summarized in Table 1. Five of these are double-blind, 
placebo-controlled randomized trials with study sizes of 
38–327 participants.50–54 All subjects experienced moderate 
to severe RLS and were either treatment-naive or discon-
tinued treatment at least 2 weeks prior to the study. The 
duration of the interventions were 14 days,50–52 12,51,54 and 
24 weeks.53 Participants were advised to take the study drug 
at 5 pm with food in all but one study due to its previously 
published improved bioavailability. Kushida et al52 split the 
drug dosing (5 pm and one hour before bedtime), testing a 
higher dose of 1800 mg daily, whereas other studies used 
either 600 mg or 1200 mg daily. The primary endpoints for 
both 14-day studies were the change in baseline International 
RLS Rating Scale (IRLS) at day 14.50,52 The rating scale is a 
validated 10 question rating scale to be filled out by patients, 
published by the International RLS study group; this helps 
grade subjective RLS symptoms and may be particularly use-
ful when assessing treatment effects.16 The other three studies 
also included investigator rated Clinical Global Impression-
Improvement (CGI-I) in addition to the IRLS.51,53,54
Four studies showed a significant improvement in their 
primary outcome measures, but the study by Walters et al 
only showed a difference with the 1200 mg/day dose and 
not with 600 mg/day.50–52,54 In contrast, the larger (n = 95 
versus 325) and longer (14 days versus 12 weeks) study by 
Lee at al did show a significant difference with 600 mg/day 
dosing. Interestingly, improvement in the coprimary end-
points were observed even at 2 weeks into the study.54 The 
fifth study was undertaken in two parts. The single-blind 
phase identified the responders to the drug, who then subse-
quently entered the double-blind phase of the study. Fewer 
relapses (9% versus 23%) were observed in patients taking 
the active study drug in comparison with placebo.53 It is 
unclear if the proportion of relapses in the placebo arm would 
have increased further beyond the 12-week duration of this 
double-blind phase.
The last two studies are both 52-week open-label stud-
ies using gabapentin enacarbil 1200 mg/day. The first is an 
extension study undertaken by Ellenbogen et al.55   Participants 
(n = 573) were enrolled from several prior gabapentin enac-
arbil studies.52–54 They consumed the study drug at 5 pm with 
food. The study had similar coprimary outcomes to those 
mentioned above and showed maintenance of symptom 
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reduction even at 52 weeks. According to 24-hour RLS dia-
ries kept by study subjects who were treatment-naive at the 
start of the trial, mean time to onset of the first RLS symptoms 
increased from 7 to 16.5 hours at week 24. No further increase 
in time to symptom onset was observed beyond week 24; 
however, more than 50% of subjects were symptom-free at 
week 24. Another study by Inoue et al also showed similar 
improvements in IRLS and CGI-I, but was performed on 
Japanese subjects.56 No comparative efficacy studies have 
been published at this time.
Adverse effects and tolerability
In all studies shown in Table 1, the most commonly 
reported treatment-emergent adverse effects were som-
nolence and dizziness. Despite this, daytime sleepiness 
based on Epworth Sleepiness Score was similar with the 
study drug and placebo.51,54 Other notable adverse effects 
include   nasopharyngitis, nausea, fatigue, sleep attacks, 
headache, insomnia, decreased libido, and diarrhea.50–56 
While there was a high incidence of treatment-emergent 
adverse effects (39%–81%), these were generally of mild to 
moderate intensity and of similar proportion to gabapentin 
(51%–82%).34,51–56 The majority of patients reported these 
effects within the first 2–4 weeks of the trial.53,56 A median 
duration of 42 days (versus 30 days with placebo) and 
13 days (versus 26 days with placebo) was reported for 
somnolence and dizziness, respectively.53 In the Inoue 
et al study, the prevalence of dizziness (0–4 weeks = 42% 
versus week 52 = 9%) and somnolence (0–4 weeks = 37% 
versus week 52 = 14%) gradually decreased over time. 
Most serious adverse effects were felt to be unrelated to 
the study drug; however, a limited number were felt to be 
related to it on the basis of a temporal relationship, includ-
ing one death due to lymphoma.56 A study investigating 
the effects of single doses of supratherapeutic gabapentin 
enacarbil of up to 6000 mg/day in healthy volunteers 
further supports its safety and   tolerability.44 All but four 
adverse effects were mild to moderate in   intensity. Two 
subjects reported sedation (4800 mg/day) and   somnolence 
(6000 mg/day), both of which were recorded as serious 
adverse events. Bogan et al reported the occurrence of 
  seizures in one patient when switching from the study 
drug to placebo during the double-blind phase of their 
study. There have been no reported significant changes 
in vital signs, hematology, electrolytes, or renal function 
with gabapentin enacarbil. In a study of 15 patients with a 
creatinine clearance , 30 mL/minute, 600 mg/day dosing 
was well tolerated.48
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
205
Gabapentin enacarbil XR in RLSTherapeutics and Clinical Risk Management 2012:8
Several secondary endpoints assess additional patient-
focused perspectives. In general, improvements in sleep 
quality, number of nights with RLS symptoms, hours 
awake as well as frequency of awakenings at night, mood, 
and patient rated CGI-I have been documented.50–52,54,56 
Kushida et al further showed an improvement in sleep archi-
tecture by polysomnography, with reduced stage 1 sleep and 
increased slow wave sleep. In the same study, 85% of subjects 
reported feeling “much improved” or “very much improved” 
compared with placebo (15%). Patient symptom diaries also 
documented a reduction in RLS intensity or RLS symptoms 
altogether.54 Overall, gabapentin enacarbil is generally safe 
and well tolerated without significant augmentation.
Practical implications
The improved pharmacokinetics of gabapentin enacarbil 
over gabapentin has been shown in several Phase 1 trials and 
animal studies, with its non-saturable absorption throughout 
the entire length of the intestine.44,46,57 Nevertheless, there 
have thus far been no comparative efficacy studies using 
these two medications. Hence, the practical benefit of its 
improved bioavailability compared with gabapentin remains 
a theoretical advantage at present.
Several Phase II and III studies using gabapentin enacarbil 
600–1800 mg/day have shown reduced RLS severity by the 
IRLS and therapeutic benefit from a physician’s perspective 
based on the CGI-I. There have also been two longer studies 
documenting continued benefit of the drug compared with 
placebo over 52 and 64 weeks. Neither of these studies docu-
mented augmentation as an issue, unlike that observed with 
most dopaminergic agents.27,28 In addition, both dopamine 
precursors and the agonist have not been shown to increase 
slow wave sleep or consistently improve overall sleep archi-
tecture despite improvement in the periodic leg movement 
index, in contrast with gabapentin enacarbil.52,58–61 Further 
studies with direct comparisons of gabapentin enacarbil and 
dopamine agonists are necessary, nonetheless.
The safety and tolerability of gabapentin enacarbil 
is acceptable, with mostly mild to moderate symptoms. 
Although the incidence of emergent adverse effects is high, 
it is comparable with gabapentin. It has also been tested in a 
small subset of patients with renal impairment. While dose 
adjustment will be necessary, doses of 600 mg/day were 
found to be well tolerated.48
Presently, gabapentin enacarbil has not been approved by 
the Therapeutic Goods Administration or Medsafe for use in 
RLS. The cost of this medication may also be a potential bar-
rier for many patients. It is twice the price of pramipexole and 
ropinirole and five times the cost of generic gabapentin in the 
United States.62 However, it is still useful with its once-daily 
dosing. Patient adherence will likely improve as a result when 
compared with the 1–3 times daily dosing of gabapentin. As 
a second-line agent, it will potentially be of most benefit in 
patients with painful RLS or in those with augmentation. 
Future comparative efficacy studies with gabapentin, first-line 
dopaminergic agents, rotigotine, being the other once-daily 
RLS medication, and pregabalin, the structural analog of 
gabapentin, will be necessary.38
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